Comparative study of molecular response of first-line and second-line nilotinib in patients with chronic-phase chronic myelogenous leukemia.

Author: Hui XU ^{1
,

2} ; Ping WANG ³ ; Rong Jun MA ⁴ ; Jian Min GUO ⁴ ; Ping Chong LEI ⁴ ; Yu Zhu ZANG ⁴ ; Tong Bao WANG ⁴ ; Zhong Wen LIU ⁴ ; Jing YANG ⁴ ; Yin ZHANG ⁴ ; Zun Min ZHU ^{5
,

6}
Author Information

1. Jinzhou Medical University, Jinzhou 121001, China
2. Hematology of Department, Henan Province People's Hospital, Zhengzhou 450003, China.
3. Hematology of Department, Xinyang Central Hospital, Xinyang 464000, China.
4. Hematology of Department, Henan Province People's Hospital, Zhengzhou 450003, China.
5. Hematology of Department, Henan Province People's Hospital, Zhengzhou 450003, China
6. Institute of Hematology, Henan Province People's Hospital, Zhengzhou 450003, China.
Publication Type:Journal Article
MeSH: Antineoplastic Agents; Dasatinib; Humans; Leukemia, Myeloid, Chronic-Phase/drug therapy*; Protein Kinase Inhibitors; Pyrimidines/therapeutic use*
From: Chinese Journal of Hematology 2019;40(6):522-525
CountryChina
Language:Chinese